Osteoporosis: drug market to decline, despite demand surge
This article was originally published in Scrip
Despite higher patient numbers and drug volumes, the anti-osteoporotic drug market is set to decline in value over the next 10 years, concludes of a new analysis to be published shortly by Datamonitor Healthcare (Market and Product Forecast: Osteoporosis).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.